Cambrex (NYSE:CBM) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday. The firm currently has a $44.00 target price on the biotechnology company’s stock. Zacks Investment Research‘s target price suggests a potential upside of 9.10% from the stock’s previous close.
According to Zacks, “Cambrex Corporation is an innovative life sciences company with a refreshingly human approach. Driven by passion, their pharmaceutical products, expertise and technologies accelerate customers’ small molecule therapeutics into markets across the world. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. Cambrex has transformed from a fine chemical manufacturer to a business with a singular focus on small molecule therapeutics. “
A number of other research firms also recently commented on CBM. TheStreet downgraded shares of Cambrex from a “b” rating to a “c+” rating in a report on Monday, December 3rd. ValuEngine downgraded shares of Cambrex from a “sell” rating to a “strong sell” rating in a report on Wednesday, December 26th. Robert W. Baird initiated coverage on shares of Cambrex in a report on Thursday, November 15th. They issued an “outperform” rating on the stock. Finally, First Analysis upgraded shares of Cambrex from an “outperform” rating to a “strong-buy” rating and dropped their target price for the stock from $73.00 to $63.00 in a report on Friday, November 9th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Cambrex currently has a consensus rating of “Buy” and an average target price of $60.83.
Cambrex (NYSE:CBM) last released its earnings results on Thursday, November 8th. The biotechnology company reported $0.49 EPS for the quarter, missing analysts’ consensus estimates of $0.59 by ($0.10). Cambrex had a return on equity of 22.20% and a net margin of 22.67%. The business had revenue of $104.62 million during the quarter, compared to the consensus estimate of $122.04 million. During the same quarter in the previous year, the firm earned $0.55 earnings per share. The firm’s revenue for the quarter was down 7.1% compared to the same quarter last year. On average, analysts anticipate that Cambrex will post 2.77 earnings per share for the current year.
Several hedge funds have recently added to or reduced their stakes in CBM. Mackenzie Financial Corp raised its holdings in shares of Cambrex by 41.2% during the fourth quarter. Mackenzie Financial Corp now owns 1,487,875 shares of the biotechnology company’s stock valued at $56,182,000 after acquiring an additional 434,406 shares during the period. Franklin Resources Inc. raised its holdings in shares of Cambrex by 117.6% during the third quarter. Franklin Resources Inc. now owns 503,600 shares of the biotechnology company’s stock valued at $34,446,000 after acquiring an additional 272,117 shares during the period. Acadian Asset Management LLC raised its holdings in shares of Cambrex by 104.3% during the third quarter. Acadian Asset Management LLC now owns 483,763 shares of the biotechnology company’s stock valued at $33,090,000 after acquiring an additional 247,016 shares during the period. Copper Rock Capital Partners LLC raised its holdings in shares of Cambrex by 161.4% during the fourth quarter. Copper Rock Capital Partners LLC now owns 391,490 shares of the biotechnology company’s stock valued at $14,771,000 after acquiring an additional 241,749 shares during the period. Finally, William Blair Investment Management LLC raised its holdings in shares of Cambrex by 9.9% during the third quarter. William Blair Investment Management LLC now owns 2,530,397 shares of the biotechnology company’s stock valued at $173,079,000 after acquiring an additional 228,059 shares during the period.
Cambrex Company Profile
Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies to innovator and generic pharmaceutical companies. Its products include generic and branded APIs, controlled substances, chiral compounds, high potency APIs, and advanced intermediates.
Further Reading: Find a Trading Strategy That Works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.